Dan Blat’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Director at Compugen in April 2022 - Present
Associate Director, Human Immuno-Oncology Bioassays at Compugen in August 2020 - April 2022
Group Leader at Immunocore in January 2018 - July 2020
Senior Scientist-Manager at Immunocore in January 2017 - December 2017
Senior Scientist at Immunocore in January 2014 - December 2016
postdoctoral fellow at Weizmann Institute of Science in July 2012 - December 2013
PhD student at Weizmann Institute of Science in August 2007 - June 2012
chemical analyst at Teva Pharmaceutical Industries Ltd. in January 2004 - December 2004
Weizmann Institute of Science, Doctor of Philosophy (Ph.D.), June 2026
Weizmann Institute of Science, M.Sc., June 2026
About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's offices are located in Israel. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN
Discover more about CompugenAssociate Director, Antibody Engineering at Compugen
Associate Director, Antibody Engineering at Compugen
(April 2025 – Present)
Director, Biostatistics and Programming at Compugen
Director, Biostatistics and Programming at Compugen
(Apr 2025 – Present)
Executive Chair of Board of Directors at Compugen
Board Member at Compugen
(Sep 2014 – Present)
Senior Vice President, Business Development at Compugen Ltd.
Senior Vice President, Technology Innovation at Compugen Ltd.
(Oct 2018 – Present)
SVP Research & Discovery at Compugen | Drug Discovery | Venture Creation | AI in Pharma
Scientific Advisory Board, Colton Multidisciplinary Center for Autoimmunity Research at Tel Aviv University
(Apr 2024 – Present)
Senior Director, Drug safety & Pharmacovigilance at Compugen
Senior Director of Drug Safety & Pharmacovigilance at Compugen
(Sep 2023 – Present)
What is Dan Blat email address?
Email Dan Blat at [email protected] and [email protected]. This email is the most updated Dan Blat's email found in 2026.
How to contact Dan Blat?
To contact Dan Blat send an email to [email protected] or [email protected]. (updated on December 27, 2025)
What company does Dan Blat work for?
Dan Blat works for Compugen.
What is Dan Blat's role at Compugen?
Dan Blat is Director
What industry does Dan Blat work in?
Dan Blat works in the Biotechnology industry.
